MediciNova Inc
MNOV1.355USD
-0.075-5.24%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
66.46MCap. mercado
PérdidaP/E TTM
Más Datos de MediciNova Inc Compañía
MediciNova, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) for neurological and other disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (e.g., methamphetamine dependence, opioid dependence, and alcohol dependence), prevention of acute respiratory distress syndrome (ARDS), and Long COVID, and MN-001 (tipelukast) for fibrotic and other diseases, such as nonalcoholic fatty liver disease (NAFLD) and idiopathic pulmonary fibrosis (IPF). The Company's pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.
Información de la empresa
Símbolo de cotizaciónMNOV
Nombre de la empresaMediciNova Inc
Fecha de salida a bolsaDec 01, 2006
Director ejecutivoDr. Yuichi Iwaki, M.D., Ph.D.
Número de empleados13
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 01
Dirección4275 Executive Square
CiudadLA JOLLA
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal92037
Teléfono18583731500
Sitio Webhttps://medicinova.com/
Símbolo de cotizaciónMNOV
Fecha de salida a bolsaDec 01, 2006
Director ejecutivoDr. Yuichi Iwaki, M.D., Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Yuichi Iwaki, M.D., Ph.D.
Dr. Yuichi Iwaki, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.09M
--
Dr. Kazuko Matsuda, M.D., Ph.D.
Dr. Kazuko Matsuda, M.D., Ph.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
323.00K
--
Dr. David H. Crean, Ph.D.
Dr. David H. Crean, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Ms. Carolyn D. Beaver
Ms. Carolyn D. Beaver
Independent Director
Independent Director
--
--
Ms. Nicole Lemerond
Ms. Nicole Lemerond
Independent Director
Independent Director
--
--
Mr. Hideki Nagao
Mr. Hideki Nagao
Independent Director
Independent Director
--
--
Mr. Jason J. Kruger
Mr. Jason J. Kruger
Chief Financial Officer
Chief Financial Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Yuichi Iwaki, M.D., Ph.D.
Dr. Yuichi Iwaki, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.09M
--
Dr. Kazuko Matsuda, M.D., Ph.D.
Dr. Kazuko Matsuda, M.D., Ph.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
323.00K
--
Dr. David H. Crean, Ph.D.
Dr. David H. Crean, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Ms. Carolyn D. Beaver
Ms. Carolyn D. Beaver
Independent Director
Independent Director
--
--
Ms. Nicole Lemerond
Ms. Nicole Lemerond
Independent Director
Independent Director
--
--
Mr. Hideki Nagao
Mr. Hideki Nagao
Independent Director
Independent Director
--
--
Desglose de ingresos
FY2024
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
0.00
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: dom., 23 de feb
Actualizado: dom., 23 de feb
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
3D Investment Partners Pte. Ltd
11.22%
EW Healthcare Partners
2.25%
Iwaki (Yuichi)
2.23%
BlackRock Institutional Trust Company, N.A.
1.41%
The Vanguard Group, Inc.
1.27%
Other
81.62%
Accionistas
Accionistas
Proporción
3D Investment Partners Pte. Ltd
11.22%
EW Healthcare Partners
2.25%
Iwaki (Yuichi)
2.23%
BlackRock Institutional Trust Company, N.A.
1.41%
The Vanguard Group, Inc.
1.27%
Other
81.62%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
14.01%
Investment Advisor/Hedge Fund
3.34%
Individual Investor
2.98%
Venture Capital
2.25%
Research Firm
1.79%
Hedge Fund
0.47%
Bank and Trust
0.02%
Other
75.13%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
68
12.20M
24.87%
-484.88K
2025Q1
73
12.20M
24.88%
-318.34K
2024Q4
74
12.23M
24.94%
+65.83K
2024Q3
73
11.92M
24.31%
+15.81K
2024Q2
76
11.78M
24.02%
-90.59K
2024Q1
75
11.47M
23.39%
-882.87K
2023Q4
77
11.84M
24.14%
-895.64K
2023Q3
90
12.02M
24.50%
-1.28M
2023Q2
106
12.39M
25.26%
-1.32M
2023Q1
131
12.60M
25.68%
-2.90M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
3D Investment Partners Pte. Ltd
5.50M
11.22%
--
--
Apr 21, 2025
EW Healthcare Partners
1.11M
2.25%
--
--
Mar 31, 2025
Iwaki (Yuichi)
1.09M
2.23%
--
--
Apr 21, 2025
BlackRock Institutional Trust Company, N.A.
691.21K
1.41%
-1.45K
-0.21%
Mar 31, 2025
The Vanguard Group, Inc.
623.57K
1.27%
+241.00
+0.04%
Mar 31, 2025
Citi Investment Research (US)
591.96K
1.21%
+90.00K
+17.93%
Mar 31, 2025
Geode Capital Management, L.L.C.
527.00K
1.07%
+12.09K
+2.35%
Mar 31, 2025
Matsuda (Kazuko)
323.00K
0.66%
--
--
Apr 21, 2025
Susquehanna International Group, LLP
250.12K
0.51%
-1.26K
-0.50%
Mar 31, 2025
UBS Financial Services, Inc.
222.20K
0.45%
-538.00
-0.24%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Micro-Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
Proporción0.01%
Avantis US Small Cap Equity ETF
Proporción0%
Dimensional US Core Equity 1 ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
